Thursday, Jul 17, 2003

Genentech Announces Senior Appointments in Research and Commercial Operations

South San Francisco, Calif. -- July 17, 2003 --

Genentech, Inc. (NYSE: DNA) announced today two senior appointments in the company's Research and Commercial Operations organizations: Andrew C. Chan is promoted to vice president, Research-Immunology and David Logan is promoted to vice president, Specialty Therapeutics.

Andrew C. Chan, vice president, Research-Immunology
Andrew Chan, 43, joined Genentech in 2001 as senior director of Immunology in the Research department. While at Genentech, Chan has been responsible for overseeing research programs focused on the role of the immune system in cancer and various immunological disorders. In his position as vice president, Research-Immunology, Chan will continue to supervise Genentech's immunology research program for the treatment of immune-mediated and inflammatory disorders. Chan's laboratory is currently working on defining the role of B-cells in autoimmune disease and understanding the mechanisms of action of anti-CD20 and other B-cell modulatory therapies.

"This promotion recognizes Andy's significant contributions to the study of immunological disorders at Genentech, as well as Genentech's continued commitment to the research and development of therapies to address immune-related diseases," said Richard Scheller, senior vice president, Research.

Chan received his bachelor's and master's degrees in chemistry from Northwestern University, and his medical degree and doctorate in cellular and developmental biology from the Washington University School of Medicine in St. Louis. He completed his internship and residency in internal medicine at Barnes Hospital at Washington University School of Medicine before becoming a postdoctoral clinical and research fellow at the University of California, San Francisco.

Prior to joining Genentech, Chan was an associate professor in the Division of Rheumatology and the Departments of Medicine, Pathology and Immunology at Washington University School of Medicine in St. Louis, where he was also a Howard Hughes Medical Institute (HHMI) associate investigator. Chan is a frequent lecturer and has authored or co-authored more than 50 scientific articles.

David Logan, vice president, Specialty Therapeutics Marketing and Sales
David Logan, 48, joined Genentech in 1987 as a clinical marketing specialist in the company's field sales force. During the next several years, Logan was appointed to several field sales positions of increasing responsibility. In 1995, Logan moved to Genentech headquarters in South San Francisco where he was named associate director of Field Managed Care and is credited with establishing Genentech's Field Managed Care group. He was promoted to senior director of Sales Operations in 1996 and then to senior director of Managed Care in 1999. Most recently, in 2001, Logan was named senior director of sales and marketing in the Specialty Therapeutics division. In his position as vice president, Specialty Therapeutics Marketing and Sales, Logan will continue to oversee all sales and marketing activities associated with Genentech's Growth Hormone franchise, Pulmozyme® the potential psoriasis treatment, Raptiva®.

"Dave has been a consistent leader who has been integral to the growth and success of the Commercial organization by focusing on the strengths of our people, products and our customers," said Diane Parks, vice president of Specialty Biotherapeutics and Managed Care. "His leadership, experience, and solid team building skills are valuable assets that will contribute to the future success of Specialty Therapeutics."

Logan holds a bachelor's degree in communications from the University of Alabama. Prior to joining Genentech, Logan held positions in sales and sales management at Pfizer Inc. after spending four years in the United States Army.

About Genentech
Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Sixteen of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes 11 biotechnology products in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA. For additional information about the company, please visit http://www.gene.com.